<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58554">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01709734</url>
  </required_header>
  <id_info>
    <org_study_id>TOK-200-10</org_study_id>
    <nct_id>NCT01709734</nct_id>
  </id_info>
  <brief_title>A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer</brief_title>
  <acronym>ARMOR2</acronym>
  <official_title>ARMOR2: A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tokai Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tokai Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2, 2 part trial to evaluate the safety and efficacy of galeterone in castration
      resistant prostate cancer (CRPC) patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will be split into two parts. The purpose of Part 1 will be to confirm dose and
      target patient population and Part 2 will be expansion of the dose and patient population
      selected in Part 1.  For eligible patients, there will be an optional extension dosing
      following the completion of Part 1 or Part 2 of the trial.

      Obtaining of informed consent and screening may be performed up to 28 days prior to
      enrollment.  Each patient will be able to receive his specified regimen for 3 consecutive
      cycles.  Each cycle consists of 28 days (approximately 1 mo.).  End of Cycle 3 visit
      assessments will be used to determine outcome and dosing may continue up to an additional 2
      weeks until the results of all assessments are obtained.  Eligible patients may continue
      treatment in an optional extension period following the completion of the primary parts of
      this trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Confirmation of recommended dose and patient population for Part 2 of the study.</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of efficacy by means of PSA response.</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Confirmation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose A - galeterone tablets once daily PO for three months + extension
Dose B - galeterone tablets once daily PO for three months + extension
Dose C - galeterone tablets once daily PO for three months + extension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose expansion (from part 1) of galeterone tablets once daily PO for three months + extension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>galeterone</intervention_name>
    <arm_group_label>Dose Confirmation</arm_group_label>
    <arm_group_label>Dose Expansion</arm_group_label>
    <other_name>TOK-001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmed adenocarcinoma of the prostate

          2. Ongoing androgen blockade demonstrated by serum testosterone concentration of less
             than 50 ng/dL

          3. Demonstration of progression while on androgen blockade

          4. Eastern Cooperative Oncology Group (ECOG) Performance Status &lt;2

        Exclusion Criteria:

          1. Depending upon patient prior treatment the following apply:

               -  Prior treatment with CYP17 inhibitors or AR antagonists (e.g. abiraterone,
                  TAK-700, ARN-509, ketoconazole*, enzalutamide, or galeterone) - Treatment na誰ve
                  only

               -  Prior treatment with CYP17 inhibitors (e.g. TAK-700, ketoconazole*) or AR
                  antagonists (e.g. enzalutamide, ARN-509,) or galeterone - abiraterone refractory
                  only

               -  Prior treatment with CYP17 inhibitors (e.g. abiraterone, TAK-700, ketoconazole*)
                  or AR antagonists (e.g. ARN -509) or galeterone - enzalutamide refractory only

          2. Prior chemotherapy (unless allowed for some study arms)

          3. Treatment with non-steroidal oral antiandrogens within 4 weeks of enrollment

          4. Prior use of any chronic systemic glucocorticoids .

          5. Prior radiation therapy within 3 weeks and radionuclide therapy within 8 weeks of
             enrollment

          6. Prior treatment with Alpharadin速 (Xofigo速)

          7. Treatment with anti arrhythmia therapy for ventricular arrhythmia &lt; 4 weeks prior to
             enrollment

          8. Treatment with Coumadin速 or other anti-coagulant therapy (except aspirin) &lt; 4 weeks
             prior to enrollment

          9. Severe systemic diseases or active uncontrolled illnesses.

         10. Abnormal heart function

         11. Liver metastases

         12. Brain metastases (unless stable disease &gt;3 mos. by scan without additional
             CNS-directed therapy)

         13. The patient has known allergy to any of the treatment components

         14. Any physical or mental condition or social situation that in the opinion of the
             Investigator may interfere with the patient's ability to comply with the trial
             procedures

         15. History of excessive alcohol consumption

         16. Use of any substance known to cause AME
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Montgomery, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington/Seattle Cancer Care Alliance</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary Ellen Taplin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA David Geffen School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-7384</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nazy Zomordian</last_name>
      <phone>310-794-3512</phone>
      <email>nzomorodian@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Phuong Nguyen</last_name>
      <phone>310-794-3452</phone>
      <email>PVNguyen@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Rettig, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Bernardino Urological Associates</name>
      <address>
        <city>San Bernardino</city>
        <state>California</state>
        <zip>92404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charity H. Hernandez, LVN</last_name>
      <phone>909-881-0555</phone>
      <email>charity@sburology.com</email>
    </contact>
    <contact_backup>
      <last_name>Roxie M. Miller, LVN</last_name>
      <phone>909-881-0555</phone>
      <email>roxie@sburology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Franklin Chu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Raton Regional Hospital, Lynn Cancer Institute</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Godbout</last_name>
      <phone>561-955-4800</phone>
      <email>sgodbout@brrh.com</email>
    </contact>
    <investigator>
      <last_name>Alan Koletsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulane Cancer Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yordanka Koleva</last_name>
      <phone>504-988-3723</phone>
      <email>ykoleva@tulane.edu</email>
    </contact>
    <contact_backup>
      <last_name>Patrick Cotogno</last_name>
      <phone>504-988-6542</phone>
      <email>pcotogno@tulane.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Oliver Sartor, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AAHS Research Institute</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Ross</last_name>
      <phone>443-481-4392</phone>
      <email>eross@aahs.org</email>
    </contact>
    <contact_backup>
      <last_name>Venita Alston Crawford, R.N.</last_name>
      <phone>443-481-4393</phone>
      <email>valstoncra@aahs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jason Taksey, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shannon Boisseau</last_name>
      <phone>410-328-7680</phone>
      <email>sboisseau@umaryland.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michele Besche</last_name>
      <phone>410-328-8610</phone>
      <email>MBESCHE@umm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Arif Hussain, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Schultz</last_name>
      <phone>410-614-9482</phone>
      <email>kschult3@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ting Wang</last_name>
      <phone>410-502-2299</phone>
      <email>Twang2@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mario Eisenberger, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Prisby, R.N.</last_name>
      <phone>617-632-5068</phone>
    </contact>
    <investigator>
      <last_name>Mary-Ellen Taplin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ted Tsacogianis</last_name>
      <phone>617-632-9279</phone>
      <email>ttsacogi@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Glenn Bubley, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jalal Syed</last_name>
      <phone>617-726-3547</phone>
      <email>jsyed@partners.org</email>
    </contact>
    <investigator>
      <last_name>Phillip Saylor, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Kadoo</last_name>
      <phone>313-576-9389</phone>
      <email>kadoot@karmanos.org</email>
    </contact>
    <contact_backup>
      <last_name>Cynthia Silski Silsk</last_name>
      <phone>313-576-9368</phone>
      <email>silskic@karmanos.org</email>
    </contact_backup>
    <investigator>
      <last_name>Elisabeth Heath, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology Cancer Center and GU Research Network</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luke Nordquist, M.D.</last_name>
      <email>drnordquist@gucancer.com</email>
    </contact>
    <contact_backup>
      <last_name>Susan Quinn, RN</last_name>
      <phone>402-991-8468</phone>
      <email>squinn@gucancer.com</email>
    </contact_backup>
    <investigator>
      <last_name>Luke Nordquist, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Urology Associates</name>
      <address>
        <city>Brick</city>
        <state>New Jersey</state>
        <zip>08724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol McGee</last_name>
      <phone>732-840-4300</phone>
      <email>cmcgee1944@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Katherine Hommes, RN</last_name>
      <phone>732 840-4300</phone>
      <email>kathyhommes@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Burzon, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premier Urology Associates, LLC</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gretchen Palacios</last_name>
      <phone>609-895-0735</phone>
      <email>gpalacios@advancement.info</email>
    </contact>
    <contact_backup>
      <last_name>Melissa Ciatteo</last_name>
      <phone>609-895-0735</phone>
      <email>mlciatteo@advancemed.info</email>
    </contact_backup>
    <investigator>
      <last_name>Gary Karlin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Center Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Healy</last_name>
      <phone>716-845-8910</phone>
      <email>eileen.healy@roswellpark.org</email>
    </contact>
    <contact_backup>
      <last_name>Diane Poslinski</last_name>
      <phone>716-845-7754</phone>
      <email>Diane.Poslinski@RoswellPark.org</email>
    </contact_backup>
    <investigator>
      <last_name>Roberto Pili, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rothschild Soto</last_name>
      <phone>212-824-7319</phone>
      <email>Rothschild.soto@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Galsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Clinical Trials</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Dziadziola</last_name>
      <phone>704-786-2931</phone>
      <email>kdziadziola@carolinaclinicaltrials.com</email>
    </contact>
    <investigator>
      <last_name>David Lipsitz, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital System University Medical Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Cantrell, RN</last_name>
      <phone>864-455-3737</phone>
      <email>cantrell@ghs.org</email>
    </contact>
    <investigator>
      <last_name>William J Edenfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Griffith</last_name>
      <phone>843-449-1010</phone>
      <phone_ext>316</phone_ext>
      <email>jgriffith@atlanticurologyclinics.com</email>
    </contact>
    <contact_backup>
      <last_name>Rebecca Floyd</last_name>
      <phone>843-449-1010</phone>
      <phone_ext>251</phone_ext>
      <email>rfloyd@atlanticurologyclinics.com</email>
    </contact_backup>
    <investigator>
      <last_name>Neal Shore, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Urology</name>
      <address>
        <city>Carollton</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urology Clinics of North Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Reeves Reeves</last_name>
      <phone>214-580-1482</phone>
      <email>reeves@urologyclinics.com</email>
    </contact>
    <contact_backup>
      <last_name>Maria Elena Sanchez</last_name>
      <phone>214-580-1482</phone>
      <email>msanchez@urologyclinics.com</email>
    </contact_backup>
    <investigator>
      <last_name>James Cochran, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington/Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Teller</last_name>
      <phone>206-598-0854</phone>
      <email>saratell@uw.edu</email>
    </contact>
    <investigator>
      <last_name>R. B. Montgomery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shane Brown</last_name>
      <phone>604-877-6000 XT2370</phone>
      <email>sbrown9@bccancer.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Kim Chi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Yin</last_name>
      <phone>416-480-5000 x7158</phone>
      <email>jessica.yim@sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <last_name>Nesan Bandali, R.N.</last_name>
      <phone>416-480-5000 x 5739</phone>
      <email>Nesan.bandali@sunnybrook.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Urban Emmenegger, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 27, 2014</lastchanged_date>
  <firstreceived_date>October 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate cancer CRPC</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
